Clinical Trial Update: SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating simultaneous integrated boost radiotherapy (SIB-RT) with CAPOX chemotherapy and a PD-1 inhibitor for high-risk rectal cancer; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• PD-1 inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: Rectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING